Introduction: Intravenous immunoglobulin (IVIg) therapy for steroid-resistant optic neuritis has been covered by health insurance, but its effectiveness and indications remain unclear. We investigated the outcome and issues of IVIg therapy in our cases.
Method: We retrospectively studied 6 patients (7 eyes) diagnosed with optic neuritis at our Department, who switched to IVIg therapy after 1-2 courses of pulse steroid therapy failed to improve visual acuity (VA) . VA, visual field and critical fusion frequency before and after therapy were analyzed.
Results: Mean age at diagnosis was 44.2 years. Two patients (2 eyes) had neuromyelitis optica spectrum disorders (NMOSD) , 2 patients (3 eyes) had myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) , and 2 patients (2 eyes) had idiopathic optic neuritis. Before treatment, minimum VA was light perception – 0.15. Five eyes had central or paracentral scotoma, and 2 eyes had only peripheral vision. After IVIg treatment, final VA improved to 1.0 or above in 5 eyes; scotoma disappeared in 5 eyes, although central scotoma remained in 1 eye. One patient each with NMOSD and MOGAD required plasmapheresis after IVIg therapy.
Discussion: Although IVIg therapy is generally effective for steroid-resistant optic neuritis, plasmapheresis may be more effective in patients with severe visual field disturbance after pulse steroid therapy.
View full abstract